- The FDA has approved Roche (OTCQX:RHHBY +0.7%) unit Foundation Medicine's FoundationOne CDx molecular test as a companion diagnostic for AstraZeneca's Lynparza (olaparib) for first-line maintenance therapy in BRCA mutation-positive ovarian cancer.
- The companies and Merck are also collaborating on developing companion diagnostics for Lynparza in prostate cancer.
FDA OKs Foundation Med's FoundationOne CDx as a companion Dx for Lynparza
Recommended For You
More Trending News
About RHHBY Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
RHHBY | - | - |
Roche Holding AG |